Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants-Reference-Cited by-同舟云学术

Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants

Published:2022-04-01 Issue:4 Volume:140 Page:337
ISSN:2168-6165
Container-title:JAMA Ophthalmology
language:en
Short-container-title:JAMA Ophthalmol

Author:

,Hartnett M. Elizabeth¹,Wallace David K.²,Dean Trevano W.³,Li Zhuokai³,Boente Charline S.²,Dosunmu Eniolami O.⁴⁵,Freedman Sharon F.⁶,Golden Richard P.⁷,Kong Lingkun⁸,Prakalapakorn S. Grace⁶,Repka Michael X.⁹,Smith Lois E.¹⁰,Wang Haibo¹,Kraker Raymond T.³,Cotter Susan A.¹¹,Holmes Jonathan M.¹²

Affiliation:

1. John A. Moran Eye Center, Salt Lake City, Utah

2. Indiana University, Indianapolis

3. Jaeb Center for Health Research, Tampa, Florida

4. Cincinnati Children’s Hospital Medical Center, Abrahamson Pediatric Eye Institute, Cincinnati, Ohio

5. Department of Ophthalmology, University of Cincinnati, Cincinnati, Ohio

6. Duke Eye Center, Durham, North Carolina

7. Nationwide Children’s Hospital, Columbus, Ohio

8. Texas Tech University Health Science Center, Lubbock

9. Wilmer Eye Institute, Baltimore, Maryland

10. Boston Children’s Hospital, Boston, Massachusetts

11. Southern California College of Optometry at Marshall B. Ketchum University, Fullerton

12. Department of Ophthalmology and Vision Science, University of Arizona, Tucson

Publisher

American Medical Association (AMA)

Subject

Ophthalmology

Link

https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2789630/jamaophthalmology_hartnett_2022_oi_220001_1649949516.64409.pdf

Reference31 articles.

1. Childhood blindness in the context of VISION 2020—the right to sight.;Gilbert;Bull World Health Organ,2001

2. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity Randomized Trial.;Early Treatment for Retinopathy of Prematurity Cooperative Group;Arch Ophthalmol,2003

3. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.;Mintz-Hittner;N Engl J Med,2011

4. Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study.;Kusaka;Br J Ophthalmol,2008

5. Intravitreal ranibizumab as a primary or a combined treatment for severe retinopathy of prematurity.;Arámbulo;Clin Ophthalmol,2015

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating VEGF-A Levels in Relation to Retinopathy of Prematurity and Treatment Effects: A Systematic Review and Meta-Analysis;Ophthalmology Science;2024-11

2. Targeting adenosine A2A receptors for early intervention of retinopathy of prematurity;Purinergic Signalling;2024-02-08

3. Retinopathy of Prematurity;Reference Module in Neuroscience and Biobehavioral Psychology;2024

4. A Network Meta-Analysis of Success Rates following Low Dosage Anti-VEGF for Retinopathy of Prematurity;Current Eye Research;2023-09-28

5. Pathophysiology of Retinopathy of Prematurity;Annual Review of Vision Science;2023-09-15